XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

JULY 11, 2023

For example, Sanofi, Pfizer, Gilead, Novartis, BMS, Genentech, and Bayer have all announced significant alliances to integrate these big data technologies into drug discovery operations. In another published report 2 , a biotech company needed to improve its centrifugation step during monoclonal antibody (mAb) harvesting.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

SEPTEMBER 6, 2022

And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. The use of big data and AL to direct the best patient candidates for CGT and to provide the best understanding of efficacy and benefits.” – ?

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

pharmaphorum

SEPTEMBER 18, 2020

Having already acquired UK-based Cambridge Antibody Technology in 2006, AstraZeneca merged these two companies to create a dedicated global biologics organisation known as MedImmune. Bestseller Nexium had become available in approximately 100 markets over the past seven years since launch. A comeback story?

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98